Clinical DevelopmentLast reviewed April 2026

Minimum Anticipated Biological Effect Level(MABEL)

The lowest dose at which a biologic is anticipated to produce any pharmacologically meaningful effect in humans, used as the basis for first-in-human starting dose for high-risk products.

Usage Examples

The MABEL-based starting dose was set at 1% of the predicted pharmacologically active dose.
Sequential single-subject dosing with 2-week observation intervals replaced the typical parallel cohort design.

What is MABEL?

MABEL is a first-in-human starting dose approach introduced by EMA (2007) and adopted by FDA in response to the 2006 TGN1412 clinical trial catastrophe where six healthy volunteers suffered life-threatening cytokine release syndrome at a dose derived from NOAEL. For high-risk biologics — novel immunomodulators, agonists targeting amplification cascades, products with non-linear PK — MABEL replaces NOAEL as the starting dose anchor.

MABEL is derived from in vitro pharmacology (receptor occupancy studies, functional assays), relevant-species PK/PD (when species selection is adequate), and clinical pharmacology modeling. Starting doses are typically 1-10% of the predicted MABEL, producing much lower starting doses than NOAEL-based approaches would generate. Sequential single-subject dosing (not parallel cohort dosing) is standard for MABEL-derived FIH trials. EU Clinical Trials Regulation and ICH S9/M3 reference the MABEL approach.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside EMA GUIDELINE FIH 2007, ICH M3, EU CTR 536 2014.

FDAEMAPMDA

When This Matters

The MABEL-based starting dose was set at 1% of the predicted pharmacologically active dose.
Sequential single-subject dosing with 2-week observation intervals replaced the typical parallel cohort design.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

EMA GUIDELINE FIH 2007ICH M3EU CTR 536 2014

Frequently Asked Questions

High-risk products: novel mechanism immunomodulators, agonists that could trigger amplification cascades (cytokine release), products with species-specific pharmacology limiting animal translation, and products targeting resting immune cells. EMA 2007 guidance lists decision criteria.

Typically yes for high-risk biologics where biological activity begins at doses well below toxicity thresholds. The whole point is to start below biological activity rather than below toxicity. For small molecules and most conventional biologics, NOAEL-derived doses remain safe and MABEL is not required.

Yes, because starting doses are lower and dose escalation proceeds more cautiously. Single-subject sequential dosing adds weeks per dose level. The trade-off is substantially reduced risk of first-dose adverse events in healthy volunteers or patients.